Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin

Chia Jung Hsieh, Tae Woo Kim, Chien Fu Hung, Jeremy Juang, Michelle Moniz, David A.K. Boyd, Liangmei He, Pei Jer Chen, Chien Hung Chen, T. C. Wu

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Vaccinia vaccines have become important vectors for antigen-specific immunotherapy. Calreticulin has been shown to enhance MHC class I presentation of linked peptide/protein and may be useful for antigen-specific cancer treatment. An innovative vaccine administering antigen linked to calreticulin via a vaccinia vector may generate a potent antigen-specific antitumor response. We tested the efficacy of linking calreticulin (CRT) to model antigen human papilloma virus type 16 (HPV-16) E7 in the context of a vaccinia vaccine (Vac-CRT/E7). Intraperitoneal vaccination of C57BL/6 mice with Vac-CRT/E7 led to a dramatic increase in E7-specific IFN-γ-secreting CD8+ T cells and a potent antitumor effect against E7-expressing tumors compared to immunization with Vac-E7 or Vac-CRT. When compared to other chimeric vaccinia vaccines employing various intracellular targeting strategies previously developed in our lab, Vac-CRT/E7 elicited the highest number of E7-specific CD8+ T cells. Thus, vaccination with vaccinia expressing CRT linked to a tumor antigen may represent an advantageous strategy for cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)3993-4001
Number of pages9
Issue number29-30
StatePublished - Sep 28 2004


  • Calreticulin
  • Cancer immunotherapy
  • Vaccinia vaccines

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin'. Together they form a unique fingerprint.

Cite this